Full text
Earnings transcript
Read the complete earnings call transcript.
NVS
Novartis AG
$149.12
2.7
(1.84%)
| Exchange: | NYSE |
| Market Cap: | 284.535B |
| Shares Outstanding: | 2.739B |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Drug Manufacturers – General | |||||
| CEO: | Vasant Narasimhan | |||||
| Full Time Employees: | 75883 | |||||
| Address: |
| |||||
| Website: | https://www.novartis.com |
Novartis AG is a global healthcare enterprise dedicated to the discovery, development, production, and distribution of medical products across the world. The company operates through two main divisions: Innovative Medicines and Sandoz. Its Innovative Medicines segment provides prescription drugs to both patients and healthcare professionals, addressing a wide array of therapeutic areas such as ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory health, cardiovascular conditions, renal disorders, and metabolic diseases. The Sandoz division is responsible for the formulation, manufacturing, and commercialization of finished dosage form medicines. It also supplies active pharmaceutical ingredients and completed small molecule pharmaceuticals to other entities, in addition to offering retail generic drugs and anti-infectives. Furthermore, Sandoz provides crucial pharmaceutical intermediates and active ingredients, predominantly antibiotics, as well as protein- and biotechnology-derived products, including biosimilars, and offers biotechnology manufacturing services. Novartis AG also engages in strategic alliances, notably a licensing and collaboration deal with Alnylam Pharmaceuticals for the development, production, and marketing of inclisiran. Additionally, it holds a clinical partnership with Kura Oncology, Inc. to assess the combined efficacy of Tipifarnib and Alpelisib in patients diagnosed with head and neck squamous cell carcinoma. Founded in 1996, the company is headquartered in Basel, Switzerland.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 46,660,000 | 51,722,000 | 54,811,252 |
| Gross Profit | 34,188,000 | 38,895,000 | 41,121,506 |
| EBITDA | 18,255,000 | 20,715,000 | 22,987,115 |
| Operating Income | 9,769,000 | 14,544,000 | 17,073,989 |
| Net Income | 14,850,000 | 11,941,000 | 14,055,610 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 99,945,000 | 102,246,000 | 115,569,198 |
| Total Liabilities | 53,195,000 | 58,120,000 | 69,020,119 |
| Total Stockholders Equity | 46,667,000 | 44,046,000 | 46,130,079 |
| Total Debt | 26,348,000 | 31,258,000 | 37,033,064 |
| Cash and Cash Equivalents | 13,393,000 | 11,459,000 | 11,435,020 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 14,458,000 | 17,619,000 | 19,242,034 |
| Capital Expenditure | -2,753,000 | -3,814,000 | -1,555,927 |
| Free Cash Flow | 11,705,000 | 13,805,000 | 17,686,107 |
| Net Income | 8,572,000 | 11,939,000 | 14,055,610 |
| Net Change in Cash | 5,876,000 | -1,934,000 | -23,998 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 68,320,807.964 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 72,342,344.439 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 69,808,857.143 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 30,771,066.665 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 32,582,329.890 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 31,441,270.398 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 23,928,672.162 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 25,771,767.963 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 24,610,654.362 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 18,121,608.868 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 19,188,292.843 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 18,516,303.340 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 12.590 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 13.180 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 12.240 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 6 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 5 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Financial Performance: Novartis reported a 7% increase in sales and core operating income for Q3 2025, as highlighted in the earnings call transcript. This growth reflects strong operational efficiency and sustained demand for key products, positioning the company favorably within the pharmaceutical sector.
- Strong Product Portfolio: The earnings call emphasized robust performance from key brands, contributing significantly to revenue growth. This indicates a diversified and resilient product lineup capable of driving consistent financial results.
- Healthy Cash Flow Metrics: Based on cash flow statement data, Novartis demonstrates solid free cash flow, supported by positive net cash provided by operating activities. This financial stability enables reinvestment in innovation and strategic initiatives.
- Strategic Acquisitions: The Q3 2025 earnings call noted strategic acquisitions as a driver of growth, enhancing Novartis’ market position and expanding its pipeline, which strengthens long-term competitiveness.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about NVS valuation
Is Novartis AG (NVS) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Novartis AG (NVS) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is NVS a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether NVS trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is NVS’s P/E ratio?
You can see NVS’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for NVS?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is NVS a good long-term investment?
Whether NVS fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
NVS
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
1.84
Trading Metrics:
| Open: | 147.19 | Previous Close: | 146.42 | |
| Day Low: | 147.05 | Day High: | 149.71 | |
| Year Low: | 112.34 | Year High: | 170.46 | |
| Price Avg 50: | 149.22 | Price Avg 200: | 141.28 | |
| Volume: | 2.367M | Average Volume: | 1.785M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeNVS full analysis
Hey everyone, welcome back to the channel! Today, we’re diving deep into a comprehensive analysis of Novartis AG, ticker NVS, one of the giants in the pharmaceutical world. If you’re looking to understand whether this stock deserves a spot in your portfolio, stick around because we’re covering everything from financials to valuation, recent performance, and more. Let’s get started! Alright, let’s set the stage. Novartis is a Swiss-based powerhouse in the healthcare sector, known for its innovative medicines and a…
